Physician profile
Montha Suphangul
NPI 1548424229
$1,031.19
in general payments reported to CMS, 2019-2025
11 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $159 · 2021: $49.24 · 2022: $25.91 · 2023: $72.45 · 2024: $111 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $293.36 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.16 | 2019-2024 | Jardiance |
| Amgen INC. | $136.94 | 2019-2025 | Repatha, Repatha |
| Lilly USA, LLC | $126.43 | 2019-2024 | Jardiance |
| Abbvie INC. | $57.03 | 2020 | |
| Exact Sciences Corporation | $47.69 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $36.93 | 2019 | |
| Ucb, INC. | $21.39 | 2021 | |
| Phadia US INC. | $17.92 | 2024 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $14.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.97 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Montha Suphangul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.